EnVision+, an ImmunoHistoChemistry reagent. This in-vitro diagnostic (reagent) is marketed both as a component in various finished assay kits and as a standalone product. Model Number K4002
This recall has been terminated (originally issued December 23, 2005).
- Company
- Dakocytomation California Inc
- Recall Initiated
- October 14, 2005
- Posted
- December 23, 2005
- Terminated
- January 29, 2007
- Recall Number
- Z-0312--06
- Quantity
- Lots 045037=113 & 065139=122
- Firm Location
- Carpinteria, CA
- Official Source
- View on FDA website ↗
Reason for Recall
This recall has been initiated due to a formulation error in the EnVision+ visualization reagent.
Distribution
Nationwide to: AK, AL, AZ, CA, CO, CT, DC, FL, GA, HI, IA, IL, IN, KS, KY, LA, MA, MD, MI, MO, MN, NC, NE, NJ, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, VT, WA, WI, and WV. Worldwide to: Argentina, Bermuda, Brazil, Canada, Costa Rica, Denmark, Japan, Mexico, New Zealand, and Uruguay.
Lot / Code Info
K4002: Lots 045037 & 065139
Root Cause
Other
Action Taken
Notification letter dated October 14, 2005 was sent by certified mail to cosignees instructing dosposal of product.
More recalls by Dakocytomation California Inc
EnVision+, an ImmunoHistoChemistry reagent. This in-vitro diagnostic (reagent) is marketed both as a...
Dec 23, 2005
EnVision+, an ImmunoHistoChemistry reagent. This in-vitro diagnostic (reagent) is marketed both as a...
Dec 23, 2005
EnVision+, an ImmunoHistoChemistry reagent. This in-vitro diagnostic (reagent) is marketed both as a...
Dec 23, 2005